FDx Advisors Inc. Sells 454 Shares of Natera, Inc. (NASDAQ:NTRA)

FDx Advisors Inc. reduced its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 8.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,655 shares of the medical research company’s stock after selling 454 shares during the quarter. FDx Advisors Inc.’s holdings in Natera were worth $504,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Principal Securities Inc. purchased a new stake in Natera in the fourth quarter worth about $32,000. GAMMA Investing LLC boosted its stake in Natera by 50.0% during the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after buying an additional 108 shares during the last quarter. YHB Investment Advisors Inc. bought a new stake in shares of Natera in the 1st quarter valued at approximately $36,000. Tobam bought a new stake in shares of Natera in the 2nd quarter valued at approximately $74,000. Finally, DekaBank Deutsche Girozentrale bought a new stake in shares of Natera in the 1st quarter valued at approximately $83,000. 99.90% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Steven Leonard Chapman sold 6,105 shares of the company’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $111.61, for a total value of $681,379.05. Following the sale, the chief executive officer now owns 213,351 shares in the company, valued at approximately $23,812,105.11. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, insider Jonathan Sheena sold 12,000 shares of the company’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $121.01, for a total value of $1,452,120.00. Following the completion of the sale, the insider now owns 287,441 shares in the company, valued at approximately $34,783,235.41. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 6,105 shares of the stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $111.61, for a total transaction of $681,379.05. Following the completion of the sale, the chief executive officer now owns 213,351 shares of the company’s stock, valued at approximately $23,812,105.11. The disclosure for this sale can be found here. Insiders have sold 92,388 shares of company stock worth $10,205,064 in the last quarter. 7.60% of the stock is owned by corporate insiders.

Natera Trading Down 0.6 %

Shares of Natera stock opened at $113.24 on Thursday. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $124.83. The company has a market capitalization of $13.91 billion, a P/E ratio of -36.29 and a beta of 1.48. The business has a 50 day moving average price of $111.34 and a 200 day moving average price of $101.60.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.39. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The company had revenue of $413.35 million during the quarter, compared to analysts’ expectations of $343.00 million. During the same period in the previous year, the company earned ($0.97) EPS. The business’s quarterly revenue was up 58.1% compared to the same quarter last year. Sell-side analysts anticipate that Natera, Inc. will post -2.03 EPS for the current fiscal year.

Analyst Ratings Changes

NTRA has been the topic of several research reports. Stephens restated an “overweight” rating and set a $125.00 price objective on shares of Natera in a report on Friday, August 9th. UBS Group lowered their price objective on Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Morgan Stanley lifted their price target on Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. Robert W. Baird lifted their price objective on Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Finally, TD Cowen lifted their price target on Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Natera has an average rating of “Moderate Buy” and a consensus price target of $120.07.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.